New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
11:07 EDTTEF, SKUL, STI, NVAX, PHigh option volume stocks: TEF SKUL STI NVAX P
News For TEF;SKUL;STI;NVAX;P From The Last 14 Days
Check below for free stories on TEF;SKUL;STI;NVAX;P the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
07:58 EDTPPandora outlook has improved, says Oppenheimer
Subscribe for More Information
September 11, 2014
15:45 EDTPPandora management getting savvier on content costs, says Maxim
Maxim said Pandora's (P) new multi-year rights agreement with BMG supports its view that management is getting more savvy on managing content costs. The firm also thinks the tone of Apple (AAPL) at its launch event suggests its service has yet to gain traction as a competitor to Pandora and that comments from Sirius XM's (SIRI) CFO indicate Pandora is gaining traction in car integration. The firm maintains it Buy rating and $35 price target on Pandora.
09:01 EDTPPandora strikes U.S. licensing deal with BMG
Subscribe for More Information
September 10, 2014
06:24 EDTTEFAmazon to debut Fire Phone in U.K.
Subscribe for More Information
September 9, 2014
11:34 EDTTEFVivendi considers stake in Mediaset TV unit, Bloomberg reports
Subscribe for More Information
11:22 EDTTEFVivendi considers stake in Mediaset TV unit, Bloomberg reports
Subscribe for More Information
11:22 EDTSTISunTrust sees modest decline potential in cyclical costs, other expenses
Says committed to maintaining strong expense discipline. Says that there is potential for modest declines in cyclical costs and other credit-related expenses. Believes company's size is an advantage. In terms of the company's consumer banking and private wealth management area, it looks to grow wealth management, optimize the delivery model, increase consumer lending production and continue to improve retail productivity. Says that there is further potential in improving the company's overall return profile and capital return to shareholders. Comments take from the company's slide presentation at the Barclays 2014 Global Financial Services Conference.
06:03 EDTTEFTelefonica to trial AT&T's connected home technology in Europe
AT&T (T) and Telefonica (TEF) last night announced plans for a limited trial of AT&T's home security and automation service in Europe. By licensing the AT&T Digital Life platform, Telefonica can offer trial users a wireless home automation platform all managed through an easy-to-use, web-based user interface. AT&T independently owns its platform, allowing for others to license a turnkey solution. AT&T Digital Life is an IP-based, all wireless, home security, smart automation and energy management solution, all contained in an easy-to-use mobile app. Telefonica is the first company to license AT&T's Digital Life platform.
September 8, 2014
07:35 EDTTEFAmazon mulls Fire phone UK exclusively deal with O2, FT says
In an effort to rival Apple (AAPL) and Samsung (SSNLF) in the premium smartphone industry, Amazon (AMZN) is in final-stage discussions to sell its new Fire smartphone exclusively through Telefonica’s (TEF) O2 throughout the UK, reported the Financial Times. Reference Link
07:24 EDTSTIBarclays to hold a conference
Global Financial Services Conference to be held in New York on September 8-10.
September 7, 2014
12:31 EDTNVAXNovavax presents data on RSV F nanoparticle vaccine induced monoclonal antibody
Novavax presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab, Syangis, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody.", Novavax used its RSV F vaccine to generate a murine monoclonal antibody, NVX4C6, that binds to the antigenic site II on the RSV F-protein. Using Surface Plasmon Resonance, Novavax was able to compare the binding affinity of NVX4C6 and palivizumab to the antigenic site II. This experiment demonstrated that Novavax' RSV F vaccine can induce antibodies to the antigenic site II that have a higher binding affinity to the site than palivizumab. In addition, NVX4C6 was shown to have a slightly different specificity to the site II epitope and to recognize mutated site II peptide not recognized by palivizumab, suggesting that NVX4C6 may neutralize palivizumab escape mutants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use